Vaxcyte, Inc.
Vaxcyte, Inc. (PCVX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
pcvx · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$89.00
Consensus
$89.00
+94.8% upside
Low
$89.00
Median: $89 · Last Close: $45.69
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $44.09 | ↓ 3.50% |
1-day model range: $43.81–$44.37. Peak: $44.37 (-3.50%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $79 | +72.4% |
| 2028 | $113 | +147.3% |
| 2029 | $142 | +211.8% |
| 2030 | $165 | +260.6% |
| 2031 | — | +294.4% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PCVX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-02-26 | BTIG | Maintains | Buy→Buy |
| 2026-02-02 | Guggenheim | Maintains | Buy→Buy |
| 2025-11-10 | BTIG | Maintains | Buy→Buy |
| 2025-10-16 | BTIG | Maintains | Buy→Buy |
| 2025-04-08 | Needham | Maintains | Buy→Buy |
| 2025-04-01 | Needham | Maintains | Buy→Buy |
| 2025-04-01 | B of A Securities | Maintains | Buy→Buy |
| 2025-04-01 | Goldman Sachs | Maintains | Buy→Buy |
| 2025-03-12 | Guggenheim | Maintains | Buy→Buy |
| 2025-02-26 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Vaxcyte, Inc. (PCVX) stock. Of the recent 45 rating actions, 0 were upgrades and 0 were downgrades. 11 analysts currently cover PCVX.
Analyst Recommendation Trends
PCVX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$25M
↓ 85.9% YoY
Revenue Next Year
$87M
↑ 248.6% YoY
EPS This Year
$-8.13
EPS Next Year
$-6.67
↓ 18.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast PCVX EPS of $-8.13 for the current fiscal year, based on estimates from 6 analysts. The PCVX revenue forecast is $25M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PCVX stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PCVX price target is $89.00 (+94.8% upside), with an analyst consensus of Buy.
The PCVX short-term stock prediction for tomorrow is $44.09 (-3.50%). The PCVX stock price prediction for 2027 estimates an average of $79. The PCVX stock prediction for 2030 projects a range of $153–$176.
Vaxcyte, Inc. trades on NASDAQ under the ticker PCVX. The PCVX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
PCVX forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month PCVX price target is $89.00, with a high forecast of $89.00 and a low of $89.00. The median price target is shown in the chart above when available. This implies +94.8% potential upside from the current price of $45.69.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.